Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Real-World Retention Rates After Intravesical OnabotulinumtoxinA for Idiopathic Overactive Bladder

Liberman, Daniel; Milhouse, Olufenwa; Johnson-Mitchell, Marta; Siegel, Steven W.

Obstetrical & Gynecological Survey: April 2019 - Volume 74 - Issue 4 - p 209–210
doi: 10.1097/OGX.0000000000000669

(Abstracted from Female Pelvic Med Reconstr Surg 2018;24:404–407)

Intravesical onabotulinumtoxinA (BoNT-A) is used for treatment of idiopathic overactive bladder (iOAB) when conservative measures and medications fail to improve symptoms. After intravesical BoNT-A, the risk of incomplete bladder evacuation (IBE) requiring catheterization is well established.

Metro Urology, Woodbury, MN

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.